The global market size of rat model is expected to reach $1.7

New York, Nov. 22, 2022 (GLOBE NEWSWIRE) — Announces Release of Report “Global Rat Model Market Size Analysis Report, Share and Industry Trends by Technology, by Type, by Service, by Application, by Use final, by geographical area Outlook and forecasts, 2022 – 2028″ –
Therefore, genome-wide research on human aggression is essential. However, genome-wide investigations related to aggression have only been done in animals, not people. The rat has a larger brain and more sophisticated behavioral repertoire, but retains many tractable traits that make it suitable for laboratory research.

Rats are the first mammalian species domesticated expressly for laboratory purposes. Scientists employed the brown rat Rattus norvegicus to study human physiology and medicine two centuries ago, focusing on the effects of food and oxygen deprivation. In the domains of physiology, pharmacology, immunology, toxicology, nutrition, behavior and learning, rats have been used to address a number of fundamental scientific concerns regarding prevalent human diseases.

The laboratory mouse has been the preferred model in many biological areas for decades. Numerous inbred variants have been isolated, exhibiting a broad spectrum of characteristics and serving as models for a variety of human characteristics and disorders. Mapping and genomics of the rat genome have progressed significantly in recent decades. Numerous investigations aimed at identifying disease-causing genes through positional identification have been prompted by the availability of this data.

Numerous rat genes have now been identified that underlie monogenic or complex diseases, and surprisingly, these findings have been translated into humans in a significant proportion of cases, leading to the discovery of new genetic variants of human diseases, aiding in the study of the mechanisms underlying pathological abnormalities and suggesting new therapeutic approaches. Also, reverse genetics techniques have been created. Several genome editing techniques have been developed to induce targeted mutations in genes whose function can then be understood.

COVID-19 impact analysis

The COVID-19 pandemic has had a beneficial effect on market growth. There has been a significant surge in investment and funding from the government and major players to develop COVID-19 infection detection and treatment plans. This growth is directly related to the increase in studies and research activities for the development of new vaccines and diagnostics. In 2020, for example, Mirimus Inc., an innovative animal model company, partnered with an academic group of researchers. To study the entry mechanism of the SARS-CoV-2 virus, these scientists constructed a rat model containing human ACE2 receptors. These efforts reflect the expanding use of the rat model to elucidate disease pathogenesis and advance the development of treatments.

Market growth factor

An increasing number of advances within the rat model

Multiple behavioral and neurological impairments are caused by total deletion of the maternal UBE3A gene in a new rat model of Angelman syndrome (AS). This model could be useful for gaining a better understanding of AS and evaluating potential treatments. The AS model was created in rats by removing the entire maternal UBE3A gene. Furthermore, a rat model of AS has advantages over a mouse model because the social behavior of rats is more human-like than that of mice.

The rapid development of complex rat genome manipulation approaches

Preclinical animal models, such as mice and rats, are needed to predict the efficacy and toxicity of human drugs. Rats are often used due to their genetic similarity to humans, infinite availability, and ease of handling. The production of knockout rats involves inactivating/silencing or deleting an existing gene and then replacing it with a synthetic fragment of DNA, resulting in inactivation of the gene. This results in changes to the phenotypic traits of the rat, including its appearance, behavior and other observable biochemical characteristics.

Market restrictive factor

An increasing number of challenges and complexities in exploiting this approach

In terms of the diseases they are used to investigate, rats are generally not the model of preference in terms of disorders related to tumors, blood and immunological function. Rats are, however, the model of choice when it comes to ailments associated with aging. On the other hand, they are most commonly used in the research of cardiovascular and metabolic diseases, as well as in the early stages of conditions related to the brain, digestive system, and a variety of behavior-related health problems.

Outlook technology

Based on the technology, the rat model market is categorized into Nuclear Transferase, Embryonic Stem Cell and Microinjection and CRISPR/CAS and others. In 2021, the microinjection segment had a promising revenue share of the rat models market. the use of microinjection to directly introduce these nucleases into fertilized embryos eliminates the need to edit stem cells and saves time. Companies are offering custom rat model generation services to capitalize on this market trend.

Type Outlook

On the basis of type, the rat model market is segregated into Knockout, Outbred, Inbred, Hybrid, Immunodeficient, and Conditioned. In 2021, the inbred segment has garnered a promising share of revenue in the rat model market. The widespread use of the inbred rat model in toxicology research and the stable genomic structure of the segment contribute to its expansion. By using a limited number of inbred models of different strains, a toxicology study can produce extensive data. The knockout strain is expected to undergo a significant increase in growth.

Service Outlook

By service, the rat model market is segmented into cryopreservation, breeding derivation, genetic testing, quarantine addiction, and more. In 2021, the Animal Husbandry segment captured the largest share of the rat model market revenue. This is a result of the growing demand for rat models in scientific experiments and investigations. Several factors contribute to the growth of this segment, including uniformity in genome structure, behavior, and ease of manipulation.

Application Outlook

Based on the application, the rat model market is segmented into oncology, neurology, immunology, toxicology, and more. In 2020, the oncology segment garnered a substantial share of the revenue of the rat model market. Various elements of the progression, genesis and clinical course of human neoplasms are modeled using rats and mice. As a result, they serve as important models for cancer researchers engaged in basic, translational, clinical and epidemiology research.

Stop using Outlook

Based on end use, the rat model market is segmented into CROs, research and academic institutions, and pharmaceutical and biotechnology companies. In 2021, the CRO segment had the highest revenue share of the rat model market. This is due to the increased outsourcing of clinical and preclinical trials by healthcare companies and the consequent increase in the number of CROs. With varying product development schedules and the need to improve timeliness to market, pharmaceutical and biotechnology companies typically outsource rat model trials and tests to CROs.

Regional perspective

Regionally, the rat model market has been analyzed in North America, Europe, Asia-Pacific and LAMEA. In 2021, North America held the highest revenue share of the rat model market. The increasing frequency of chronic diseases, the emergence of new infectious strains and rising health care costs in North America are expected to stimulate research in the region. The increase in the number of research activities carried out by academic and research institutions is expected to stimulate regional growth.

The market research report covers the analysis of the key stakeholders of the market. Key companies profiled in the report include Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings, Inotiv, Inc., genOway, Janvier Labs, Taconic Biosciences, Inc. (HIG Capital), TransViragen, Inc., Biomedical Research Models, Inc. (Biomer) and Cyagen Biosciences

Purpose of the study

Market segments covered in the report:

By technology

• CRISPR/CAS and others

• Nuclear transferase

• Embryonic stem cells and microinjection

By type

• Hybrid

• Hybrid

• To stun

• Inbred

• Immunodeficiency

• Conditional

For service

• farm

• Genetic testing

• Cryopreservation

• Re-derivation

• Depending on the quarantine and more

By application

• Toxicology

• Oncology

• Immunology

• Neurology and others

For final use


• Pharmaceutical and biotech companies

• Academic and research institutions

By Geography

• North America

United States

Oh Canada

oh mexico

o Rest of North America

• Europe

or Germany

or UK

oh france

or Russia

or Spain

or Italy

o Rest of Europe

• Asia Pacific

oh China

oh Japan

oh India

or South Korea

or Singapore

or Malaysia

o Rest of Asia Pacific


oh brazil

or Argentina

or United Arab Emirates

or Saudi Arabia

or South Africa

or Nigeria

o Rest of LAMEA

Profiled company

• Charles River Laboratories International, Inc.

• Laboratory Company of the Holdings of America

• Inotiv, Inc.

• genOway

• Janvier laboratories

• Taconic Biosciences, Inc. (HIGH Capital)

• TransViragen, Inc.

• Biomedical Research Models, Inc. (biomeric)

• Cyagen Biosciences

Unique offers

• Comprehensive coverage

• More tables and market data

• Subscription-based model available

• Best Price Guaranteed

• Assured after-sales research support with 10% free customization
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need, instantly, in one place.




Leave a Comment

%d bloggers like this: